Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-163

have followed MSB for a while and not a current holder (will be soon though). This announcement is fantastic and backs up recent work done by MSB. two things are certain
- this will generate global news and interest in this stock - the results are significant
- Remestemcel-L use for ARDS patients will increase dramatically now based on compassionate grounds.

well done to holders and MSB. I see the previous pattern for MSB is for the SPP to retrace after a positive announcement, but this announcement and environment is different IMO. the share price should sharply increase over coming days and weeks, this announcement is a globally significant announcement (even based on small numbers). great work!